Sensus Healthcare
Sensus Healthcare (NASDAQ: SRTS) develops and sells proprietary low-energy Superficial Radiation Therapy (SRT) systems for the non-invasive, in-office treatment of non-melanoma skin cancer and keloids, sold to dermatology and oncology practices in the US and internationally.
- Company typePublic
- Founded2010
- HeadquartersBoca Raton, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sensus Healthcare does
Sensus Healthcare, Inc. (NASDAQ: SRTS) is a Florida-incorporated, Boca Raton-headquartered medical device company founded in 2010 that designs, manufactures, and sells Superficial Radiation Therapy (SRT) systems for the non-invasive treatment of non-melanoma skin cancer (basal cell and squamous cell carcinomas) and keloids. Its core technology is a proprietary low-energy X-ray platform with more than a decade of R&D, marketed through three hardware SKUs—the original SRT-100, the SRT-100+, and the SRT-100 Vision, the last of which adds high-frequency ultrasound imaging (marketed as IG-SRT) for procedure planning. The devices are FDA 510(k) cleared, require no consumables, and run on standard electrical outlets.
The company generates revenue primarily through capital equipment sales (Q4 2025 shipped 14 units, 8 US / 6 international; Q3 2025 shipped 16 including China-bound units) into dermatology and oncology practices, supplemented by an in-house financing/leasing program (Sensus Healthcare Financial Services, launched February 2026) and a newly launched cloud software platform (Sensus Link, February 2026) intended to drive subscription recurring revenue. Underpinning customer economics is a major reimbursement milestone: CMS established dedicated CPT codes for SRT and IG-SRT effective January 1, 2026, with approximately 300% per-fraction delivery code value uplift that lowers practice breakeven to about one patient per month. Sensus also expanded into adjacent aesthetics through 2024 acquisitions of mobile aesthetic laser companies.
The company is led by co-founder and CEO Joseph C. Sardano, with President/General Counsel Michael Sardano promoted in November 2025 to also serve as Chief Commercial Officer; the board was expanded to six members in January 2026 with the addition of GE HealthCare's Larry Biscotti. Operationally Sensus holds $22.1M in cash entering 2026 with zero debt, but reported FY2025 revenue of $27.5M (down 34% from $41.8M in FY2024), Q1 2026 revenue of $3.4M (-59% year-over-year) following loss of its historically largest customer, and a securities-law investigation by Bragar Eagel & Squire tied to the Q2 2025 earnings miss.
Sensus Healthcare firmographics
Firmographics- Name
- Sensus Healthcare
- Legal name
- Sensus Healthcare, Inc.
- Website
- https://sensushealthcare.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Sensus Healthcare (NASDAQ: SRTS) develops and sells proprietary low-energy Superficial Radiation Therapy (SRT) systems for the non-invasive, in-office treatment of non-melanoma skin cancer and keloids, sold to dermatology and oncology practices in the US and internationally.
- Ownership category
- akta.pro rank
Sensus Healthcare industry classification
Industry- Product category
- Radiotherapy Medical Devices
- NAICS
- Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Outpatient Rehabilitation & Physical/Occupational/Speech Therapy Centers (HLAFABAB)
- akta.pro secondary industry
- Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)
Keywords
Where Sensus Healthcare is headquartered
LocationHeadquarters
- HQ city
- Boca Raton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sensus Healthcare business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Marketing or Sales, Technology or R&D, Personnel, Operations
Revenue model
- SRT System Sales: Sale of SRT-100, SRT-100+, and SRT-100 Vision radiotherapy systems to dermatology and oncology practices. Hardware sales constitute primary revenue. Q4 2025 shipped 14 units (8 US, 6 international). Q3 2025 shipped 16 units including exports to China.
- Software (Sensus Link): Cloud-based software add-on for radiotherapy systems. Part of strategic shift to recurring revenue model. Rollout planned for 2026.
- Financing Services: Sensus Healthcare Financial Services offers flexible purchase or leasing options for dermatology practices acquiring SRT systems. Fair market value leases replace conventional bank financing.
- Per-Fraction Treatment Reimbursement: CMS established new dedicated CPT codes for SRT and IG-SRT effective January 1, 2026 with approximately 300% increase in per-fraction delivery code values. Creates recurring reimbursement revenue stream for practices using the technology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Flexible purchase or leasing options through Sensus Healthcare Financial Services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Sensus Healthcare product offering
Product offeringCore offering
Sensus Healthcare designs, manufactures, and sells proprietary Superficial Radiation Therapy (SRT) medical devices—the SRT-100, SRT-100+, and SRT-100 Vision—for non-invasive treatment of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) and keloids. The company also offers the Sensus Link cloud-based software platform and an in-house financing program (Sensus Healthcare Financial Services) to support practice adoption.
Product overview
Sensus Healthcare offers a portfolio of three Superficial Radiotherapy (SRT) medical devices—the SRT-100, SRT-100+, and SRT-100 Vision—all using proprietary low-energy X-ray technology to treat non-melanoma skin cancer and keloids non-invasively. The SRT-100 is the original compact system; the SRT-100+ offers enhanced state-of-the-art features; and the SRT-100 Vision adds image-guidance via high-frequency ultrasound (also known as IG-SRT). The company has expanded into software with Sensus Link, a cloud-based platform launched in 2026 to create recurring revenue, and Sensus Healthcare Financial Services, a financing program to facilitate system acquisition. SRT Practice Advantage provides marketing support to purchasing physicians. All products are designed for use in dermatology and oncology practices.
Differentiator
Problem solved
Functional benefit
Brands
- Sensus Link: Cloud-based software solution for radiotherapy systems designed to create recurring revenue streams.
- Sensus Healthcare Financial Services
Products and services
- SRT-100 Original Superficial Radiotherapy system delivering precise, calibrated low-dose X-ray radiation that only penetrates skin deep (5mm). FDA-cleared for non-invasive treatment of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) and keloids. Compact 30" x 30" footprint with no consumables required; plugs into standard wall socket.
- SRT-100+ State-of-the-art Superficial Radiotherapy system for non-melanoma skin cancer and keloid treatment. Compact, efficient, and designed with patients and physicians in mind. Harnesses the same SRT technology as the SRT-100 with enhanced features for ease of use.
- SRT-100 Vision (IG-SRT) Advanced Superficial Radiotherapy system featuring all capabilities of the SRT-100 with additional high-frequency ultrasound imaging for precise treatment planning. Also referred to as IG-SRT (Image-Guided Superficial Radiotherapy). Particularly valuable for treating lesions in cosmetically sensitive areas.
- Sensus Link Cloud-based software platform for Sensus radiotherapy systems, part of strategic shift to create recurring revenue. Provides practice management and treatment tracking capabilities for healthcare providers using SRT systems.
- Sensus Healthcare Financial Services Financing program offering flexible purchase or leasing options including fair market value leases for dermatology practices acquiring SRT systems. Designed to replace conventional bank financing that often requires personal guarantees, reducing administrative and financing barriers.
Quantifiable outcome
- 98.7%+ cure rate for non-melanoma skin cancer
- +4 more outcomes
Companies that use Sensus Healthcare
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Sensus Healthcare technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Sensus Healthcare partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- SkinCure OncologyminorFormer customer relationship that deteriorated into legal dispute. Sensus Healthcare filed lawsuit against SkinCure Oncology in Florida for breach of contract, alleging unpaid amounts for medical equipment used since August 2025. Company seeks to recover millions of dollars and related damages. Legal action unlikely to affect ongoing operations or global strategy.
- MedIQ Healthcare Solutions, LLCcoreSensus Healthcare partners with MedIQ Healthcare Solutions, LLC to provide reimbursement support for all customers. MedIQ offers billing support services including phone hotline (888-462-5197) and email ([email protected]) Monday through Friday 8:30 AM to 6:00 PM EST. This partnership addresses the complex reimbursement landscape for SRT treatments, supporting customer success.
Scale indicators14 records
Recent moves8 records
Expansion highlights6 records
Sensus Healthcare competitors and assessment
Company assessmentDirect peers
- Xstrahl: Xstrahl manufactures superficial and orthovoltage radiation therapy systems used to treat non-melanoma skin cancer and other superficial conditions. It is the most direct head-to-head competitor to Sensus's SRT-100/+/Vision product family.
- IntraOp Medical: IntraOp Medical manufactures specialized radiation therapy systems (Mobetron) for intraoperative and superficial electron therapy. It shares Sensus's niche positioning as a focused radiation therapy device company addressing specific clinical indications rather than full radiotherapy suites.
Broad incumbents
- Elekta: Elekta is a global leader in radiation therapy and radiosurgery hardware and software (linear accelerators, brachytherapy, treatment planning). It competes broadly in the same radiation oncology category as Sensus, though at much larger scale and across deeper indications.
- Varian (a Siemens Healthineers company): Varian, now part of Siemens Healthineers, is the leading global radiation oncology platform with linear accelerators, treatment planning, and oncology software. It addresses a much broader modality set than Sensus but competes for the same radiation oncology capital budget.
- Accuray: Accuray develops CyberKnife and TomoTherapy radiation therapy systems for stereotactic and image-guided treatments. While focused on intracranial and deeper-tissue indications, it competes for radiation oncology capital dollars and overlaps with image-guided therapy concepts behind IG-SRT.
- ViewRay: ViewRay developed the MRIdian MR-guided radiation therapy system combining real-time MRI with linear accelerator delivery. While targeted at a different indication set, its image-guided approach is conceptually adjacent to Sensus's IG-SRT value proposition.
- Carl Zeiss Meditec: Carl Zeiss Meditec operates in ophthalmology, oncology, and radiation therapy, including intraoperative radiotherapy systems. It is a broader medtech incumbent with adjacent radiation therapy products competing for hospital capital budgets.
- Eckert & Ziegler: Eckert & Ziegler manufactures radiation therapy products and radioisotope-based components for medical and industrial use. It overlaps with Sensus at the device and isotope-supply layer of the radiation therapy ecosystem.
Emerging players
- iCAD: iCAD provides AI-powered cancer detection and radiation therapy solutions, including treatment planning and oncology workflow software. It overlaps with Sensus Link's positioning as an oncology software/radiation workflow vendor.
- Novocure: Novocure's Tumor Treating Fields therapy is a non-invasive alternative oncology modality with a similar 'non-surgical' value proposition to SRT. It competes for share of voice and reimbursement attention in oncology practices.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Sensus Healthcare social profiles
Digital presenceSensus Healthcare compliance and trust
Trust signalCompliance1 record
Sensus Healthcare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sensus Healthcare leadership team
Management profileNumber of profiles
Profiles15 records
Sensus Healthcare funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sensus Healthcare M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sensus Healthcare
What does Sensus Healthcare do?
Sensus Healthcare designs, manufactures, and sells proprietary Superficial Radiation Therapy (SRT) medical devices—the SRT-100, SRT-100+, and SRT-100 Vision—for non-invasive treatment of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) and keloids. The company also offers the Sensus Link cloud-based software platform and an in-house financing program (Sensus Healthcare Financial Services) to support practice adoption.
Is Sensus Healthcare a public or private company?
Sensus Healthcare is a public company. It is classified as public and is currently operating.
When was Sensus Healthcare founded?
Sensus Healthcare was founded in 2010. It employs 51 to 100 people.
Where is Sensus Healthcare based?
Sensus Healthcare is headquartered in Boca Raton, United States, in the North America region.
How does Sensus Healthcare make money?
Four revenue lines are on record. SRT System Sales are the primary driver. The others are software (Sensus Link), financing Services and per-Fraction Treatment Reimbursement.
Who are Sensus Healthcare's main competitors?
Direct peers on record are Xstrahl and IntraOp Medical. Broad incumbents are Elekta, Varian (a Siemens Healthineers company), Accuray, ViewRay, Carl Zeiss Meditec and Eckert & Ziegler. Emerging players are iCAD and Novocure.
Does Sensus Healthcare have an API?
No public API is recorded for Sensus Healthcare.
What industry is Sensus Healthcare in?
Sensus Healthcare's product category is Radiotherapy Medical Devices. Its primary akta.pro industry code is HLAFABAB, Outpatient Rehabilitation & Physical/Occupational/Speech Therapy Centers, with a secondary code of HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems. Its NAICS code is 334517 and its SIC code is 3841.